One policy change can move an entire clinic budget.
Ryan White programs carry unusually high 340B revenue concentration in a small number of very high-cost drugs. That makes them efficient to run — and acutely exposed when a single manufacturer changes a contract pharmacy policy.
At a glance
- 01Ryan White purchases
- ~$3.1B (2025)
- 02Revenue concentration
- Very high
- 03Typical team size
- Small
- 04Key exposure
- Manufacturer policy
Concentration is both the strength and the risk
A Ryan White clinic's 340B savings often depend on a handful of antiretroviral and specialty drugs. That concentration means the program generates meaningful savings without the operational sprawl a large hospital program carries.
It also means the exposure is concentrated. When a manufacturer of one of those drugs restricts contract pharmacy access, the effect is not a percentage point of erosion — it can be a double-digit share of the program, arriving with limited notice.
Because these savings frequently fund direct patient services and staff positions, the operational consequence lands quickly. Modeling the exposure before it happens is the highest-value work we do for this segment.
Focused, proportionate, mission-aware
Ryan White programs do not need enterprise consulting. They need a small number of things done well and someone who understands what the savings are actually funding.
- Manufacturer restriction impact model across your specific top drugs
- Contract pharmacy oversight documentation proportionate to a small team
- Patient definition and eligibility documentation review
- Medicaid and ADAP interaction review, including duplicate discount prevention
- Policy set built for a clinic, not adapted down from a hospital manual
- Fractional program manager support where no internal 340B role exists
Engagements are commonly scoped to fit a specific grant line and a defined project period.
Eligibility evidence handled the way this population requires.
Ryan White clinics work with data sensitivity requirements that most general 340B guidance does not address — evidence handling has to protect patient confidentiality without weakening the eligibility record.
Ryan White 340B — common questions
01How do manufacturer restrictions affect us specifically?
More sharply than most entity types, because your savings are concentrated in fewer drugs. A restriction on one high-cost antiretroviral can remove a substantial share of program value in a single quarter. We model exposure drug by drug so the finance conversation starts with a number rather than an alarm.
02How does 340B interact with ADAP?
AIDS Drug Assistance Programs and 340B intersect in ways that vary by state, particularly around duplicate discount prevention and rebate handling. The correct approach is state-specific and should be documented in your policy set rather than handled informally.
03We are a subrecipient, not the direct grantee. Are we eligible?
Subrecipient eligibility depends on the structure of the relationship and how the funding flows. It is one of the areas where entities most often assume rather than verify. We confirm it against your grant documentation before anything else proceeds.
04Our team is three people. Is consulting even proportionate?
Scope should match the program. For most Ryan White clinics that means a focused engagement — restriction modeling, a policy review, an eligibility check — not a full enterprise program assessment. We scope down honestly rather than selling depth you do not need.
Marked up with FAQPage schema for search and AI-answer eligibility.
Next step
Know your restriction exposure before the letter arrives.
A focused model across your top drugs, sized to a clinic budget and a clinic timeline.